导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -18.61% | 4276/4773 |
| 近一周 | -6.46% | 5368/5462 |
| 近一月 | -3.94% | 2093/5421 |
| 近一季 | -4.51% | 1649/5209 |
| 近半年 | -17.49% | 4192/4920 |
| 近一年 | -26.45% | 4102/4366 |
| 近两年 | 2.58% | 2852/2954 |
| 近三年 | -31.05% | 2218/2253 |
| 成立以来 | 7.63% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.90% 4327/4961 |
-13.97% 4535/5312 |
- - |
- - |
| 2025 | -0.41% 3304/4813 |
-3.23% 3030/3635 |
1.23% 2411/4076 |
15.99% 2742/4524 |
-12.35% 4251/4813 |
| 2024 | 3.11% 1942/3463 |
-7.20% 2132/2808 |
-9.92% 2402/3014 |
32.30% 100/3129 |
-6.77% 2701/3463 |
| 2023 | -22.14% 1920/2656 |
-4.84% 2119/2280 |
-5.43% 1452/2385 |
1.75% 280/2515 |
-14.97% 2485/2655 |
| 2022 | -9.56% 179/2207 |
5.45% 34/1919 |
-7.10% 1889/2016 |
-5.53% 80/2113 |
-2.27% 1793/2208 |
| 2021 | -7.07% 1027/1822 |
-4.33% 857/1255 |
-6.11% 1280/1330 |
2.30% 438/1466 |
1.13% 1000/1822 |
| 2020 | -6.14% 971/1250 |
-12.19% 875/1028 |
6.83% 854/1067 |
6.36% 849/1164 |
-5.94% 1141/1184 |
| 2019 | 25.53% 597/1092 |
29.08% 285/754 |
-9.01% 628/804 |
-3.85% 746/850 |
11.16% 78/918 |
| 2018 | -24.79% 332/834 |
- - |
- - |
- - |
-4.68% 29/691 |
| 2017 | 9.15% 310/714 |
- - |
- - |
- - |
- - |
| 2016 | -19.83% 438/605 |
- - |
- - |
- - |
- - |
| 2015 | 33.64% 64/575 |
- - |
- - |
- - |
- - |
| 2014 | 69.06% 15/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰国证房地产行业指数A VS. 长安沪深300非周期A(740101) |